Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month
November 04 2019 - 8:00AM
Business Wire
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company, is publishing lung cancer prevention measures in an effort
to educate the public, prevent new cases and raise awareness of
lung cancer while supporting November’s Lung Cancer Awareness
Month.
Each patient’s cancer is unique, but there are some preventive
efforts that can be made to lower the risk of getting lung cancer.
The following are preventive actions that may lower the risk of
getting lung cancer:
- Do not smoke, or if you smoke, then quit smoking – Tobacco,
cigarettes and other smoking products all increase the risk of lung
cancer.
- Reduce your exposure to secondhand smoke – People who inhale
secondhand smoke are exposed to the same cancer-causing agents as
smokers, but at a reduced amount.
- Reduce your exposure to radon – Have your home tested and
treated for high radon levels, which can cause lung cancer.
- Know your family’s history with lung cancer – If you have a
family history of lung cancer, then you are at an increased risk of
getting lung cancer.
According to the World Health Organization, lung cancer is the
leading cause of cancer deaths worldwide, causing more deaths than
breast, colon, kidney, liver, prostate or skin cancers, and lung
cancer is one of the most common types of cancer. Each year, there
are more than 2 million new lung cancer cases and 1.7 million
deaths from lung cancer worldwide.
The American Cancer Society’s 2019 report states that each year
in the United States there are more than 228,000 new cases of lung
cancer and more than 142,000 deaths from lung cancer. NSCLC
represents 84 percent of all lung cancers and has a 23 percent
five-year relative survival rate. However, according to the
National Cancer Institute, 57 percent of lung cancer diagnoses are
distant, or have metastasized, and the five-year relative survival
rate for distant diagnoses is less than 5 percent.
LUNGevity Foundation points out that 10-15 percent of lung
cancer cases are in never smokers, and it is possible to get lung
cancer even if you have never smoked.
Genprex is working to put an end to this deadly disease. The
company is developing potentially life-changing technologies for
cancer patients, based upon a unique proprietary technology
platform, including Genprex’s initial product candidate, Oncoprex™
immunogene therapy for non-small cell lung cancer (NSCLC).
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. For more information, please visit the company’s web
site at www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex on cancer. Risks and uncertainties
associated with Genprex and its lead product candidate Oncoprex are
described more fully under the caption “Risk Factors” and elsewhere
in our filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. We undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191104005044/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024